ClinicalTrials.gg
Not yet recruitingNCT07068308Updated Jul 25, 2025

Effects of a Wed-based FRAIL-SM Program Among Patients With Heart Failure

An interventional study of web-based FRAIL-SM program in Heart Failure, sponsored by National Yang Ming Chiao Tung University. Not yet recruiting at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-07-25.

Sponsored by National Yang Ming Chiao Tung University · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
328
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 137 studies in Heart Failure with a site in Taiwan — 30 open to participants now, 39 under way, 14 of them phase 3. Heart Failure · Taiwan.

Planned enrollment
41st of 101
328 · median 177
Started
2026
with 9 others
No phase
49 of 137
11 open now
Primary completion
2027-05
later than 14 of 38 live
Registered
124th of 137
by date

Among the 137 studies in Heart Failure with a site in Taiwan, this one is the 41st largest by planned enrollment of the 101 interventional ones that give a count, is one of 10 that started in 2026, is one of 49 with no phase, reaches primary completion later than 14 of the 38 other live ones, and was the 124th registered.

Heart Failure

6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

30 of the 137 studies in Heart Failure with a site in Taiwan are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 137 studies in Heart Failure with a site in Taiwan, or all of them as a file.
02

Study summary

This study aims to examine the effects of web-based FRAIL-SM (Family involvement, self-Regulation skills training, Autonomy, Information sharing and Linkage, Self-Management) on frailty, self-management behaviors and quality of life in patients with heart failure and their families' heart failure knowledge, confidence, strain, and quality of life. Patients are recruited with a convenience sampling from two medical centers in Taiwan. The web-based FRAIL-SM includes Family involvement, self-Regulation, Autonomy support, Information sharing and Linkage.

Read the detailed description

A randomized controlled trial is conducted. Subjects are selected using a convenience sampling and are randomly assigned to the intervention or control group by stratified randomization according to participation of post-acute care. Patients in the intervention group will receive an 8-week web-based FRAIL-SM program. Data is collected by researchers using a structural questionnaire including frailty, heart failure knowledge, self-care of heart failure, and quality of life and physical indicators such as levels of B-type natriuretic peptide, hemoglobin, hematocrit, albumin at baseline, 4 weeks, 8 weeks, 12 weeks and 24 weeks after enrollment.

03

Conditions studied

  • Heart Failure

Keywords

  • frailty
  • heart failure
  • self-management
  • web-based frailty self-management program
  • knowledge
  • family caregiver
  • quality of life
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Patients criteria:

Inclusion Criteria:

  1. Aged above 20.
  2. Diagnosed with heart failure or \<40%.
  3. Clear consciousness, can communicate with Chinese and Taiwanese.
  4. Consent to join in this study and have family partner.
  5. Access to computer or smartphone
  6. Meet one of the Study of Osteoporotic Fractures of frailty

Exclusion Criteria:

  1. Bed-ridden or unable to perform activities of daily living independently.
  2. Diagnosed with cognitive, psychiatric disease, or major depression.
  3. Acute disease condition e.g. infection or thrombosis.
  4. of performing exercise such as uncontrolled hypertension, uncontrolled arrhythmia.
  5. severe neurodegenerative or muscular diseases, e.g. parkinson's disease, arthritis.

Family criteria:

Inclusion criteria

  1. Aged above 20.
  2. Clear consciousness, can communicate with Chinese and Taiwanese.
  3. Consent to join in this study and willing to accompany with patients.
  4. Access to computer or smartphone

Exclusion Criteria:

  1. Bed-ridden or unable to perform activities of daily living independently.
  2. Diagnosed with cognitive, psychiatric disease, or major depression.
  3. Have employment relationship with patients
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
328 participants (estimated)

Study arms

  • Experimental
    wed-based FRAIL-SM program

    Patients in the intervention group will receive an 8-week web-based FRAIL-SM program including family involvement, self-regulation, autonomy support, information sharing and linkage.

    Behavioral: web-based FRAIL-SM program

  • No intervention
    control group

    Patients in this group will receive usual care.

Interventions

  • Behavioralweb-based FRAIL-SM program

    The 8-week web-based FRAIL-SM includes family involvement, self-regulation, autonomy support, information sharing and linkage.

06

What researchers measure

Primary outcomes

  1. Changes in Frailty Assessment Scale for Heart Failure scores

    Changes from baseline Frailty Assessment Scale for Heart Failure scores to at 4 weeks, 8 weeks, 12 weeks and 24 weeks after enrollment. The Frailty Assessment Scale for Heart Failure contains 15 items, each item use Likert scale four point scoring (0-3), the total scores ranged from 0 to 45, the higher scores indicate higher levels of frailty.

    Time frame: baseline, 4 weeks, 8 weeks, 12 weeks, 24 weeks

  2. Changes in Dutch Heart Failure Knowledge Scale scores

    Changes from baseline Dutch Heart Failure Knowledge Scale scores to at 4 weeks, 8 weeks, 12 weeks and 24 weeks after enrollment. The Dutch Heart Failure Knowledge Scale contains 15 items. The total scores ranged from 0 to 15, the higher scores indicate higher levels of knowledge.

    Time frame: baseline, 4 weeks, 8 weeks, 12 weeks, 24 weeks

  3. Changes in Self-Care of Heart Failure Index scores

    Changes from baseline Self-Care of Heart Failure Index scores to at 4 weeks, 8 weeks, 12 weeks and 24 weeks after enrollment. The Self-Care of Heart Failure Index contains 22 items, three subscales: self-care maintenance, self-care management, self-care confidence. Each subscale scores ranged from 0 to 100, the higher scores indicate higher levels of self-care maintenance, self-care management, self-care confidence.

    Time frame: baseline, 4 weeks, 8 weeks, 12 weeks, 24 weeks

  4. Changes in Minnesota Living with Heart Failure questionnaire scores

    Changes from baseline Minnesota Living with Heart Failure questionnaire scores to at 4 weeks, 8 weeks, 12 weeks and 24 weeks after enrollment. The Minnesota Living with Heart Failure questionnaire contains 21 items, each item scores ranged from 0 to 5. The total socre ranged from 0 to 105, the higher scores indicate higher levels of impact on quality of life.

    Time frame: baseline, 4 weeks, 8 weeks, 12 weeks, 24 weeks

Secondary outcomes

  1. Changes in World Health Organization Quality of Life - BREF (WHOQOL-BREF) scale scores

    Changes from baseline World Health Organization Quality of Life - BREF (WHOQOL-BREF) Scale scores to at 4 weeks, 8 weeks, 12 weeks and 24 weeks after enrollment. The WHOQOL-BREF scale contains 28 items, four dimensions. Each dimension scores ranged from 4 to 20, the higher scores indicate higher levels of quality of life.

    Time frame: baseline, 4 weeks, 8 weeks, 12 weeks, 24 weeks

  2. Changes in Caregiver Strain Index scores

    Changes from baseline Caregiver Strain Index scores to at 4 weeks, 8 weeks, 12 weeks and 24 weeks after enrollment. The Scale contains 13 items, the total scores ranged from 0 to 13, the higher scores indicate higher levels of strain.

    Time frame: baseline, 4 weeks, 8 weeks, 12 weeks and 24 weeks

Other outcomes

  1. Changes in Hospital Anxiety and Depression Scale scores

    Changes from baseline Hospital Anxiety and Depression Scale scores to at 4 weeks, 8 weeks, 12 weeks and 24 weeks after enrollment. The Hospital Anxiety and Depression Scale contains 14 items, two subscales: anxiety and depression. Each subscale scores ranged from 0 to 21, the higher scores indicate higher levels of anxiety and depression.

    Time frame: baseline, 4 weeks, 8 weeks, 12 weeks, 24 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for May 2027, 16 months later.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 16 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2025
First posted
Jul 16, 2025
StartEst.
Jan 1, 2026
Primary completionEst.
May 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Jul 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07068308
Responsible party
Sponsor
First posted
Jul 16, 2025
Start date
Jan 1, 2026 (estimated)
Primary completion
May 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Jul 25, 2025

Study contacts

Ai-Fu Chiou, PhD
Contact
afchiou@nycu.edu.tw
886-2-28267354

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion